

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV - SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cohava Gelber (b) (6)
Sent: Tuesday, February 25, 2020 8:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

Dear Dr. Fauci,

(b) (4)